Combined radioligand binding and light microscope autoradiography techniques were used for investigating the pharmacological profile and the microanatomical localisation of dopamine receptor subtypes in the cardiovascular system and in the kidney. In superior mesenteric and renal arteries the predominant dopamine D1-like receptor belongs to the D5 (or Dib) subtype. This site is located within smooth muscle of the tunica media. The same receptor subtype predominates in the kidney, where it has a vascular and tubular localisation. The dopamine D2-like receptor subtype expressed by systemic arteries belongs to the D2 receptor subtype. It has a prejunctional and endothelial localisation. In the kidney the predominating dopamine D2-like receptor belongs to the dopamine D3 subtype. Atria but not ventricles express dopamine D2-like receptors belonging to the D4 receptor subtype. The above results suggest that in spite of the emerging complexity of the dopamine receptor profile demonstrated by molecular biology techniques, radioligand binding and autoradiographic techniques, if performed with appropriate radioligands and/or in the presence of compounds active on specific receptor subtypes, may represent a useful tool for better understanding the biological significance of peripheral dopamine receptors. The catecholamine dopamine exerts cardiac, vascular and renal effects mediated by the interaction with specific dopamine receptors localised in the cardiovascular system and in the kidney (1). Cardiac actions of dopamine include increase of myocardial contractility and cardiac output without a concomitant augmentation of heart rate (2). At the vascular level dopamine causes vasodilatation. The vasodilatory activity of dopamine is a direct mechanism, mediated through its interaction with receptors located within arterial smooth muscle and an indirect mechanism. This last consists in the reduction of the sympathetic vasoconstrictor tone, by decreasing noradrenaline release from sympathetic neuroeffector junctions (1). In the kidney dopamine causes natriuresis and vasodilatation (3).
The catecholamine dopamine exerts cardiac, vascular and renal effects mediated by the interaction with specific dopamine receptors localised in the cardiovascular system and in the kidney (1). Cardiac actions of dopamine include increase of myocardial contractility and cardiac output without a concomitant augmentation of heart rate (2). At the vascular level dopamine causes vasodilatation. The vasodilatory activity of dopamine is a direct mechanism, mediated through its interaction with receptors located within arterial smooth muscle and an indirect mechanism. This last consists in the reduction of the sympathetic vasoconstrictor tone, by decreasing noradrenaline release from sympathetic neuroeffector junctions (1). In the kidney dopamine causes natriuresis and vasodilatation (3).
Peripheral dopamine receptors were divided, on the basis of functional and pharmacological evidence, into two main subtypes, namely dopamine DA1 and DA2 receptors (4). These receptors were considered to be similar but not identical to the homologous central dopamine D1 and D2 receptors (4) . Although the classification of peripheral dopamine receptors proposed by Goldberg and Kohli (4) was not completely satisfactory for explaining the overall cardiovascular and renal actions of dopamine, it meet the general agreement of investigators and was widely used for defining cardiovascular and renal responses to dopamine (1).
From a biochemical point of view, activation of dopamine DA1 receptors results in stimulation of adenylate cyclase and phospholipase C activities in a number of tissues (1, 3). Activation of dopamine DA2 receptors results in inhibition or lack of effect on adenylate cyclase activity (1, 3).
Our group has been involved in the pharmacological characterisation and microanatomical localisation of dopamine receptors in the cardiovascular system and in the kidney using radioligand binding techniques associated with light microscope autoradiography (1). From these studies, performed both in laboratory animals and in human tissues, we have observed in systemic arteries the localisation of dopamine DA1 receptors within smooth muscle of the tunica media. In contrast, dopamine DA2 receptors showed a double localisation, adventitial (prejunctional) and endothelial (non-prejunctional) ( 1). The functional significance of endothelial dopamine DA2 sites, if any, has not been established yet (1). The above classification of peripheral dopamine receptors is not satisfactory at the present. The application of molecular biology techniques to dopamine receptor research has enlarged our knowledge about the subtypes of dopamine receptors. In fact, at least five genes encoding dopamine receptors I (1995) have been identified, which express different receptors so far included in the family of dopamine D1 (now defined dopamine Di-like) and of dopamine D2 (now defined dopamine D2-like) receptors. The majority of molecular biology studies on the characterisation of dopamine receptor subtypes has been accomplished in the brain, whereas less information is so far available for peripheral dopamine receptors (5). In this paper, our main data on radioligand binding characterisation and microanatomical localisation of peripheral dopamine receptors are detailed.
Dopamine D1-like Receptors
The dopamine D1-like receptor family comprises the dopamine D1 (or Dia) and D5 (or Dib) sites (6). In general, the sensitivities of the cloned D 1 and D5 receptors are similar (7), and the characterisation of these subtypes of dopamine receptors is difficult since they are labelled by the same radioligands with a similar degree of affinity (6, 7). The main difference is in the sensitivity of dopamine D1-like radioligands to dopamine in the micromolar range at the dopamine D1 receptor and in the submicromolar range at the dopamine D5 receptor (6, 7).
In our laboratory we have characterised the subtypes of dopamine D1-like receptors in sections of rat superior mesenteric artery and of human and rat renal artery and kidney using [3Hj-SCH 23390 as a ligand. The radioligand was bound to these tissues in a manner consistent with the labelling of dopamine D1-like receptors (Fig. 1) . Analysis of the pharmacological profile of [3H]-SCH 23390 binding to sections of superior mesenteric artery and kidney revealed the displacement of the radioligand by dopamine in the submicromolar range (Table 1) . This suggests that the majority of dopamine D1-like sites in these structures belong to the dopamine D5 receptor subtype. Microanatomical analysis of the localisation of these sites revealed their accumulation primarily within smooth muscle of the tunica media of systemic arteries (Fig. 2) and within cortical tubules of the nephron (data not shown).
From the above findings it appears that smooth muscle of the tunica media of systemic arteries and epithelial cells of renal cortical tubules express primarily a dopamine D5 receptor. Further work is in progress to assess, by radioligand binding and autoradiographic techniques, the presence of mixed populations of dopamine D1 and D5 receptors in systemic arteries and in the different portions of the nephron.
Dopamine D2-like Receptors
The dopamine D2-like receptor family includes two isoforms of the dopamine D2 receptor, the so called dopamine Des and D2L sites, and the dopamine D3 and D4 receptor subtypes (6, 7). In our laboratory, we have characterised dopamine D2-like receptors in sections of rat superior mesenteric artery and of human and 3 rat kidney using the lion-selective radioligand [ H] -spiroperidol . Both in 3the superior mesenteric artery and in the kidney , [ H]-spiroperidol was specifically bound in a manner consistent with the labelling of dopamine D2-like receptors (Fig. 3) .
Analysis of displacement curves of [3H]-spiroperidol binding to sections of the superior mesenteric arteries showed that quinpirole which has greater affinity for dopamine D3 receptor in the brain is less potent competitor of [3Hj-spiroperidol binding than dopamine D2 receptor active compounds such as haloperidol or ( -)-sulpiride (Table 2 ). In contrast, in the kidney, quinpirole had a pharmacological profile consistent with that reported for dopamine D3 receptor in the brain (Table 2 ). These findings suggest 3 that whereas in the superior mesenteric artery
[ H]spiroperidol binds mainly a dopamine D 2 receptor, a dopamine D3 site is predominant in the kidney.
To confirm the presence of a dopamine D3 receptor in the kidney, we have further characterised it in another series of experiments using [3HJ-7-OH-DPAT as a ligand. This compound is considered the most selective ligand for dopamine D3 receptor available at the present (8). Analysis of [3H]-7-OH-DPAT saturation curve shows that it labels a single population of high affinity sites (Fig. 4) . Pharmacological characterisation of [3H]-7-OH-DPAT binding to sections of rat kidney revealed a typical dopamine D3 receptor profile (8), being non-labelled 7-OH-DPAT the most powerful competitor of the radioligand followed by haloperidol, ( + )-butaclamol and quinpirole (Table 3 ). In summary, the above data strongly support the view of expression by rat kidney of a dopamine D3 receptor. The func- tional nature of this site (vasodilator, natriuretic ?) and the localisation (pre-junctional ?) should be clarified in future studies.
Light microscope autoradiography of dopamine D2-like receptors in the superior mesenteric artery and in the kidney has shown their adventitial and intimal localisation in different sized arterial branches and a tubular localisation in the kidney (data not shown) . Further quantitative autoradiographic analysis is necessary to assess whether other small populations of dopamine D2-like receptor subtypes are expressed by arterial tissue or the kidney.
Our analysis was extended also to dopamine D2-like receptors of the heart. It is known that dopamine is a potent stimulant of certain cardiac functions. The catecholamine as well as dopaminergic compounds have been proposed in the treatment of heart failure (9). Dopamine D2-like receptors have been shown in sections of human heart (9). More recently, the occurrence of a dopamine D4 receptor in the rat heart has been demonstrated with in situ hybridisation techniques (10). We have therefore ana- lysed the binding of the dopamine D4 receptor radioligand [3H]-clozapine to sections of rat atria and ventricles. F 3H]-Clozapine was specifically bound to sections of rat atria (Fig. 5 ), but not of ventricles (data not shown). The binding profile was consistent with the labelling of a dopamine D4 receptor, being unlabelled haloperidol the most powerful displacer of the radioligand followed by clozapine YM 09151-2, (+ )-butaclamol.
apomorphine, quinpirole and dopamine (Table 4) . Compounds active on dopamine D1-like receptors such as fenoldopam and SCH 23390 were without effect (Table 4) . Light microscope autoradiography revealed the accumulation of silver grains often arranged in cluster areas within atria (data not shown) . The resolution limits of light microscope autoradiography and the lack of inclusion of denervated hearts in our experiments did not allow to establish if these sites are prejunctional. Further work is in progress to clarify this point.
Conclusions
In spite of the development of the molecular biolo- 
